ONCTERNAL THERAPEUTICS, INC.

San Diego, CA · Biotech · Defunct

ONCT-505, an oral small-molecule selective androgen receptor antagonist and degrader (DAARI) that binds the NTD of mutant androgen receptor to treat Kennedy's disease (SBMA).

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · oncternal.com

Sector: Biotech
Headquarters: San Diego, CA
Latest Form D: $6.5M, Dec 2020
Total capital: $133M

Federal grants: $5.1M; 6 awards · 2021–2024; Rank in peer group#157 of 514
Private capital raised: $128M; 8 Form D · last Dec 2020; 70 months since last filing
Federal contracts: $116K; 23 awards · Veterans Affairs, Defense; Rank in Biotech#320 of 4373
Granted patents: 6; 18 pending · first 2019; Rank in peer group#58 of 514

Capital timeline

Latest events

Aug 2024Federal grantHealth and Human S · Phase II · Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as New Potential Therapeutic for Kennedy's Disease$50K
Jan 2024Federal grantHealth and Human S · Phase II · Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease$1M
Mar 2023Federal grantHealth and Human S · Phase II · Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease$754K
Aug 2022Federal grantHealth and Human S · Phase II · First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development$1M
Sep 2021Federal grantHealth and Human S · Phase I · Selective Androgen Receptor Degraders (SARDs) as new therapeutics for spinal and bulbar muscular atrophy (SBMA)$298K
Sep 2021Federal grantHealth and Human S · Phase II · First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development$1.9M
Dec 2020Private capital raisedForm D · SEC · 8th filing$6.5M
Nov 2020Private capital raisedForm D · SEC · 7th filing$1.7M
Sep 2020Private capital raisedForm D · SEC · 6th filing$383K
Aug 2020Private capital raisedForm D · SEC · 5th filing$3.5M
Jun 2020Private capital raisedForm D · SEC · 4th filing$2.8M
Oct 2017Private capital raisedForm D · SEC · 3rd filing$48.5M
Nov 2014Private capital raisedForm D · SEC · 2nd filing$43.4M
Mar 2014Private capital raisedForm D · SEC · 1st filing$21.3M

Show 23 earlier federal awards

Oct 2017Federal contractDefense · Medical And Surgical Instruments Equipment And Supplies$45K
Nov 2015Federal contractVeterans Affairs · Igf::ct::igf Surgical Scopes Repair$16K
Feb 2012Federal contractVeterans Affairs · Resectoscope, Working Element.$8K
Sep 2008Federal contractVeterans Affairs · Small Purchase Data$142
Jul 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$285
Jul 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$199
Jun 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$199
May 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$199
Apr 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$114
Mar 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$142
Feb 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$142
Feb 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$142
Jan 2008Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$85
Dec 2007Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$114
Dec 2007Federal contractVeterans Affairs · Pharmacy Ostomy Product Dispenser$5K
Dec 2007Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$114
Nov 2007Federal contractVeterans Affairs · For The Payment Of Ostomy Products Dispensed And D$6K
Nov 2007Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$85
Oct 2007Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$114
Oct 2007Federal contractVeterans Affairs · For The Payment Of Ostomy Products Dispensed And D$7K
Oct 2007Federal contractVeterans Affairs · For The Payment Of Ostomy Products Dispensed And D$4K
Oct 2007Federal contractVeterans Affairs · Soap,body,aloe VESTA,LIQUID,4 Ounce,bottle,body W$114
Oct 2007Federal contractVeterans Affairs · For The Payment Of Ostomy Products Dispensed And D$23K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

77months

from ONCTERNAL THERAPEUTICS, INC.’s first federal award to its first private round.

First federal award · Oct 2007: Veterans Affairs · $23K
First Form D · Mar 2014: $21.3M · 1st Form D
Awards before first raise: 21 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#157 · top 31%
Granted patents#58 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Brian B. LannuttiResearcherExecutive OfficerLinked by 3 patents
Gunnar F. KaufmannResearcherExecutive OfficerLinked by $2.2M in grants as PI
Gunnar F. KaufmannResearcherExecutive OfficerLinked by $2.2M in grants as PI
Cam B. GallagherDirectorNamed in SEC Form D filings
Cam F. GarnerDirectorNamed in SEC Form D filings
Charles R. TheuerDirectorNamed in SEC Form D filings

Show all 32 people

Charles G. Theuer, M.D.DirectorNamed in SEC Form D filings
Cooper R. CollinsDirectorNamed in SEC Form D filings
Dana B. McGowanExecutive OfficerNamed in SEC Form D filings
Daniel G. Kisner, M.D.DirectorNamed in SEC Form D filings
David F. HaleDirectorNamed in SEC Form D filings
David F. HaleDirectorNamed in SEC Form D filings
David B. JohnsonDirectorNamed in SEC Form D filings
Frank Hsu, M.D.Executive OfficerNamed in SEC Form D filings
Haxel M. AkerExecutive OfficerNamed in SEC Form D filings
Hazel M. AkerExecutive OfficerNamed in SEC Form D filings
Igor B. Bilinsky, Ph.D.Executive OfficerNamed in SEC Form D filings
James B. Breitmeyer, M.D., Ph.D.Director, Executive OfficerNamed in SEC Form D filings
James B. Breitmeyer, M.D., Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
James G. FreddoExecutive OfficerNamed in SEC Form D filings
Karen F. LundgrenExecutive OfficerNamed in SEC Form D filings
Langdon G. MillerExecutive OfficerNamed in SEC Form D filings
Lauren G. OtsukiExecutive OfficerNamed in SEC Form D filings
Man ChoDirectorNamed in SEC Form D filings
Michael G. Carter, M.D., ChB, FRCPDirectorNamed in SEC Form D filings
Michael G. Carter, M.D., ChB, FRCPDirectorNamed in SEC Form D filings
Richard B. VincentExecutive OfficerNamed in SEC Form D filings
Robert R. Wills, Ph.D.DirectorNamed in SEC Form D filings
Scott L. GlennDirectorNamed in SEC Form D filings
William R. LaRueDirectorNamed in SEC Form D filings
William R. LaRueDirectorNamed in SEC Form D filings
Xin R. Nakanishi, Ph.D.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 6 granted of 24

Dec 10, 2024GrantedUses Of Indolinone CompoundsUSPTOUS 12,161,626
Oct 29, 2024GrantedSelective Androgen Receptor Degrader (sard) Ligands And Methods Of Use ThereofUSPTOUS 12,128,026
Sep 15, 2022PendingIndolinone Compounds And Uses ThereofUSPTOApplication 17830668

Show all 24 patent records

Uses Of Indolinone CompoundsDec 10, 2024 · US 12,161,626Granted
Selective Androgen Receptor Degrader (sard) Ligands And Methods Of Use ThereofOct 29, 2024 · US 12,128,026Granted
Indolinone Compounds And Uses ThereofSep 15, 2022 · Application 17830668Pending
Uses Of Indolinone CompoundsMar 29, 2022 · US 11,285,132Granted
Selective Androgen Receptor Degrader (sard) Ligands And Methods Of Use ThereofJul 1, 2021 · Application 17055988Pending
Indoline Analogs And Uses ThereofJul 14, 2020 · US 10,711,008Granted
Uses Of Indolinone CompoundsMay 12, 2020 · US 10,646,470Granted
Indoline Analogs And Uses ThereofJul 16, 2019 · US 10,351,569Granted
Indolinone Compounds And Uses ThereofSep 13, 2018 · Application 15973110Pending
Antibody FormulationsApplication 18877628Pending
Combinations Of Egfr Inhibitors And ROR1 Inhibitors For The Treatment Of CancerApplication 63011036Pending
Selective Androgen Receptor Degrader (sard) Ligands And Methods Of Use ThereofApplication 62981520Pending
Combinations Of Egfr Inhibitors And ROR1 Inhibitors For The Treatment Of CancerApplication 62968121Pending
Selective Androgen Receptor Degrader (sard) Ligands And Methods Of Use ThereofApplication PCTUS2019054886Pending
A Method Of Treating Er Mutant Expressing Breast Cancers With Selective Androgen Receptor Modulators (sarms)Application PCTUS2019044550Pending
Combinations Of Egfr Inhibitors And ROR1 Inhibitors For The Treatment Of CancerApplication PCTUS2021015749Pending
Combination Therapies For The Treatment Of CancerApplication PCTUS2023084937Pending
Glycoengineered Forms Of ROR-1 Modalities And Methods Of UseApplication 63607456Pending
Glycoengineered Forms Of ROR-1 Modalities And Methods Of UseApplication 63517088Pending
Antibody FormulationsApplication PCTUS2023068932Pending
Combination Treatment Methods For Cancer With TP53 MutationApplication PCTUS2023068368Pending
Combination Treatment Methods For Cancer With TP53 MutationApplication 63487193Pending
Combination Therapies For The Treatment Of CancerApplication 63476333Pending
Antibody FormulationsApplication 63367195Pending

NEUROSETTA LLCSimilar federal contract value in Biotech · $135K in contracts
Corcept TherapeuticsSimilar federal contract value in Biotech · $132K in contracts
Akcea TherapeuticsSimilar federal contract value in Biotech · $129K in contracts
Advanced Targeting SystemsSimilar federal contract value in Biotech · $114K in contracts
Arrayit CorpSimilar federal contract value in Biotech · $114K in contracts
CLAREMONT BIOSOLUTIONS LLCSimilar federal contract value in Biotech · $111K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.